Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 0.55 |
| ▸ | KIT | P10721 | 3/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 9/20 | 0.54 |
| ▸ | SRC | P12931 | 3/20 | 0.51 |
| ▸ | LCK | P06239 | 3/20 | 0.51 |
| ▸ | INSR | P06213 | 2/20 | 0.51 |
| ▸ | LYN | P07948 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | HCK | P08631 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.49 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.49 |
| ▸ | BMX | P51813 | 2/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.48 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1704030 | 0.87 | LCK (0.59) | CSF1RKITBRAFSRCLCK | |
| SCHEMBL13878752 | 0.85 | CSF1R (0.57) | CSF1RBTKBRAFSRCLCK | |
| SCHEMBL1704263 | 0.84 | SIK1 (0.56) | CSF1RKITBTKBRAFSRC | |
| SCHEMBL13878743 | 0.84 | LYN (0.51) | CSF1RBRAFSRCLCKINSR | |
| SCHEMBL1704444 | 0.84 | LCK (0.61) | BRAFLCK | |
| SCHEMBL13878812 | 0.84 | LCK (0.61) | CSF1RKITBTKBRAFSRC | |
| SCHEMBL13878724 | 0.83 | BRAF (0.64) | CSF1RKITBTKBRAFSRC | |
| SCHEMBL1704880 | 0.83 | ABL1 (0.64) | CSF1RKITBTKBRAFSRC | |
| SCHEMBL13878730 | 0.83 | LCK (0.55) | CSF1RKITBTKBRAFSRC | |
| SCHEMBL30197903 | 0.81 | ABL1 (0.65) | CSF1RKITBTKBRAFSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | CSF1R 891/4885KIT 683/4885BTK 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.